Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations

详细信息    查看全文

• 作者：Francesca Maria Rizzo ; Raffaele Palmirotta ; Andrea Marzullo ; Nicoletta Resta…
• 关键词：Gastrointestinal stromal tumors ; DOG1 ; Size ; Mutation ; Prognostic value ; Risk
• 刊名：BMC Cancer
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：1,361 KB
• 参考文献：1.Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80.CrossRef PubMed
  2.Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.CrossRef PubMed
  3.Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245–66.CrossRef PubMed
  4.Jones RL. Practical aspects of risk assessment in gastrointestinal stromal tumors. J Gastrointest Cancer. 2014;45(3):262–7.PubMedCentral CrossRef PubMed
  5.Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33(5):459–65.CrossRef PubMed
  6.Nannini M, Astolfi A, Urbini M, Indio V, Santini D, Heinrich MC, et al. Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST). BMC Cancer. 2014;14:685.PubMedCentral CrossRef PubMed
  7.Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, et al. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res. 2012;18(6):1769–76.CrossRef PubMed
  8.Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, et al. Molecular characterization of an Italian series of sporadic GISTs. Gastric Cancer. 2013;16(4):596–601.CrossRef PubMed
  9.Lasota J, Xi L, Coates T, Dennis R, Evbuomwan MO, Wang ZF, et al. No KRAS mutations found in gastrointestinal stromal tumors (GISTs): molecular genetic study of 514 cases. Mod Pathol. 2013;26(11):1488–91.CrossRef PubMed
  10.Hechtman JF, Zehir A, Mitchell T, Borsu L, Singer S, Tap W, et al. Novel oncogene and tumor suppressor mutations in KIT and PDGFRA wild type gastrointestinal stromal tumors revealed by next generation sequencing. Genes Chromosomes Cancer. 2015;54(3):177–84.CrossRef PubMed
  11.Cole WC. ANO1-ther brick in the wall--role of Ca2 + −activated Cl- channels of interstitial cells of Cajal in cholinergic motor control of gastrointestinal smooth muscle. J Physiol. 2011;589(Pt 19):4641–2.PubMedCentral CrossRef PubMed
  12.Katoh M. FLJ10261 gene, located within the CCND1-EMS1 locus on human chromosome 11q13, encodes the eight-transmembrane protein homologous to C12orf3, C11orf25 and FLJ34272 gene products. Int J Oncol. 2003;22(6):1375–81.PubMed
  13.Novelli M, Rossi S, Rodriguez-Justo M, Taniere P, Seddon B, Toffolatti L, et al. DOG1 and CD117 are the antibodies of choice in the diagnosis of gastrointestinal stromal tumours. Histopathology. 2010;57(2):259–70.CrossRef PubMed
  14.Stanich JE, Gibbons SJ, Eisenman ST, Bardsley MR, Rock JR, Harfe BD, et al. Ano1 as a regulator of proliferation. Am J Physiol Gastrointest Liver Physiol. 2011;301(6):G1044–51.PubMedCentral CrossRef PubMed
  15.Duvvuri U, Shiwarski DJ, Xiao D, Bertrand C, Huang X, Edinger RS, et al. TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res. 2012;72(13):3270–81.PubMedCentral CrossRef PubMed
  16.Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Mühlenberg T, et al. DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors. Cancer Res. 2013;73(12):3661–70.PubMedCentral CrossRef PubMed
  17.Wada T, Tanabe S, Ishido K, Higuchi K, Sasaki T, Katada C, et al. DOG1 is useful for diagnosis of KIT-negative gastrointestinal stromal tumor of stomach. World J Gastroenterol. 2013;19(47):9133–6.PubMedCentral CrossRef PubMed
  18.Liegl B, Hornick JL, Corless CL, Fletcher CD. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol. 2009;33(3):437–46.CrossRef PubMed
  19.Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: a study of 1840 cases. Am J Surg Pathol. 2009;33(9):1401–8.CrossRef PubMed
  20.Sui XL, Wang H, Sun XW. Expression of DOG1, CD117 and PDGFRA in gastrointestinal stromal tumors and correlations with clinicopathology. Asian Pac J Cancer Prev. 2012;13(4):1389–93.CrossRef PubMed
  21.Espinosa I, Lee CH, Kim MK, Rouse BT, Subramanian S, Montgomery K, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32(2):210–8.CrossRef PubMed
  22.Sözütek D, Yanık S, Akkoca AN, Sözütek A, Ozdemir ZT, Avşar CU, et al. Diagnostic and prognostic roles of DOG1 and Ki-67, in GIST patients with localized or advanced/metastatic disease. Int J Clin Exp Med. 2014;7(7):1914–22.PubMedCentral PubMed
  23.Allred DC, Clark GM, Elledge R, Fuqua SA, Brown RW, Chamness GC, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85(3):200–6.CrossRef PubMed
  24.Yang YD, Cho H, Koo JY, Tak MH, Cho Y, Shim WS, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature. 2008;455(7217):1210–5.CrossRef PubMed
  25.Hartzell C, Putzier I, Arreola J. Calcium-activated chloride channels. Annu Rev Plant Physiol Plant Mol Biol. 2005;67:719–58.
  26.Beattie J, Allan GJ, Lochrie JD, Flint DJ. Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J. 2006;395(1):1–19.PubMedCentral CrossRef PubMed
  27.Hwang DG, Qian X, Hornick JL. DOG1 antibody is a highly sensitive and specific marker for gastrointestinal stromal tumors in cytology cell blocks. Am J Clin Pathol. 2011;135(3):448–53.CrossRef PubMed
  28.Kang YN, Jung HR, Hwang I. Clinicopathological and immunohistochemical features of gastointestinal stromal tumors. Cancer Res Treat. 2010;42(3):135–43.PubMedCentral CrossRef PubMed
  29.Franquemont DW. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol. 1995;103(1):41–7.PubMed
  30.Agaimy A, Märkl B, Arnholdt H, Hartmann A, Schneider-Stock R, Chetty R. Sporadic segmental interstitial cell of Cajal hyperplasia (microscopic GIST) with unusual diffuse longitudinal growth replacing the muscularis propria: differential diagnosis to hereditary GIST syndromes. Int J Clin Exp Pathol. 2010;3(5):549–56.PubMedCentral PubMed
  31.Maki RG. The rule of fives, a simple way to stratify risk for primary gastrointestinal stromal tumors (GIST). Clin Sarcoma Res. 2012;2(1):21.PubMedCentral CrossRef PubMed
  32.Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol. 2005;13(3):205–20.CrossRef PubMed
  33.Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or nomalignant potential. Lab Invest. 2004;84(7):874–83.CrossRef PubMed
  34.Zong L, Chen P. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis. World J Surg Oncol. 2014;12:71.PubMedCentral CrossRef PubMed
  35.Ríos-Moreno MJ, Jaramillo S, Pereira Gallardo S, Vallejo A, Mora M, García-Escudero A, et al. Gastrointestinal stromal tumors (GISTs): CD117, DOG-1 and PKCθ expression. Is there any advantage in using several markers? Pathol Res Pract. 2012;208(2):74–81.CrossRef PubMed
  36.Abdel-Hadi M, Bessa SS, Hamam SM. Evaluation of the novel monoclonal antibody against DOG1 as a diagnostic marker for gastrointestinal stromal tumors. J Egypt Natl Canc Inst. 2009;21(3):237–47.PubMed
  37.Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005;2(1):e17.PubMedCentral CrossRef PubMed
  
• 作者单位：Francesca Maria Rizzo (1)
  Raffaele Palmirotta (1) (2)
  Andrea Marzullo (3)
  Nicoletta Resta (4)
  Mauro Cives (1)
  Marco Tucci (1)
  Franco Silvestris (1)
  
  1. Department of Biomedical Sciences and Human Oncology, University of Bari “A. Moro”, Piazza Giulio Cesare, 11-70124, Bari, Italy
  2. University San Raffaele Rome, Interinstitutional Multidisciplinary BioBank (BioBIM), IRCCS San Raffaele Pisana, Rome, Italy
  3. Department of Pathology, University of Bari “A. Moro”, Bari, Italy
  4. Division of Medical Genetics, Department of Biomedical Sciences and Human Oncology, University of Bari “A. Moro”, Bari, Italy
  
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background Gastrointestinal stromal tumors (GISTs) are characterized by mutations of KIT (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog) or PDGFRA (platelet-derived growth factor receptor α) that may be efficiently targeted by tyrosine kinase inhibitors (TKI). Notwithstanding the early responsiveness to TKI, the majority of GISTs progress, imposing the need for alternative therapeutic strategies. DOG1 (discovered on GIST-1) shows a higher sensitivity as a diagnostic marker than KIT, however its prognostic role has been little investigated.